The mTOR pathway negatively controls ATM by up-regulating miRNAs

Hallmarks of Cancer: The Next Generation

Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · see citing works

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216 · see citing works

TOR signaling in growth and metabolism

Wullschleger, S., Loewith, R., & Hall, M. N. (2006) · Cell · doi:10.1016/j.cell.2006.01.016 · Cited by 5,787 · see citing works

The DNA Damage Response: Making It Safe to Play with Knives

Ciccia, A., & Elledge, S. J. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.019 · Cited by 4,368 · see citing works

mTOR: from growth signal integration to cancer, diabetes and ageing

Zoncu, R., Efeyan, A., & Sabatini, D. M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3025 · Cited by 3,941 · see citing works

The cancer genome

Stratton, M. R., Campbell, P. J., & Futreal, P. A. (2009) · Nature · doi:10.1038/nature07943 · Cited by 3,459 · see citing works

The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

Engelman, J. A., Luo, J., & Cantley, L. C. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1879 · Cited by 3,330 · see citing works

Blinded by the Light: The Growing Complexity of p53

Vousden, K. H., & Prives, C. (2009) · Cell · doi:10.1016/j.cell.2009.04.037 · Cited by 3,163 · see citing works

Cell-cycle checkpoints and cancer

Kastan, M. B., & Bartek, J. (2004) · Nature · doi:10.1038/nature03097 · Cited by 2,836 · see citing works

DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis

Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688 · see citing works

p53 in health and disease

Vousden, K. H., & Lane, D. P. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2147 · Cited by 2,275 · see citing works

Ras, PI(3)K and mTOR signalling controls tumour cell growth

Shaw, R. J., & Cantley, L. C. (2006) · Nature · doi:10.1038/nature04869 · Cited by 2,019 · see citing works

Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions

Gorgoulis, V. G., Vassiliou, L.-V. F., Karakaidos, P., Zacharatos, P., Kotsinas, A., Liloglou, T., Venere, M., DiTullio, R. A., Kastrinakis, N. G., Levy, B., et al. (2005) · Nature · doi:10.1038/nature03485 · Cited by 2,009 · see citing works

The first 30 years of p53: growing ever more complex.

Levine, A. J., & Oren, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2723 · Cited by 1,967 · see citing works

The multistep nature of cancer

Vogelstein, B., & Kinzler, K. W. (1993) · Trends in Genetics · doi:10.1016/0168-9525(93)90209-z · Cited by 1,858 · see citing works

Principles of cancer therapy: oncogene and non-oncogene addiction

Luo, J., Solimini, N. L., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.02.024 · Cited by 1,765 · see citing works

Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex

Brugarolas, J., Lei, K., Hurley, R. L., Manning, B. D., Reiling, J. H., Hafen, E., Witters, L. A., Ellisen, L. W., & Kaelin, W. G. (2004) · Genes & Development · doi:10.1101/gad.1256804 · Cited by 1,384 · see citing works

p53 Target Genes Sestrin1 and Sestrin2 Connect Genotoxic Stress and mTOR Signaling

Budanov, A. V., & Karin, M. (2008) · Cell · doi:10.1016/j.cell.2008.06.028 · Cited by 1,326 · cited 1× · see citing works

The tor pathway: a target for cancer therapy

Bjornsti, M., & Houghton, P. J. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1362 · Cited by 1,301 · see citing works

The coordinate regulation of the p53 and mTOR pathways in cells

Feng, Z., Zhang, H., Levine, A. J., & Jin, S. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502857102 · Cited by 1,235 · see citing works

The microcosmos of cancer

Lujambio, A., & Lowe, S. W. (2012) · Nature · doi:10.1038/nature10888 · Cited by 1,084 · see citing works

Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster

Dews, M., Homayouni, A., Yu, D., Murphy, D. A., Sevignani, C., Wentzel, E. A., Furth, E. E., Lee, W. M., Enders, G. H., Mendell, J. T., et al. (2006) · Nature Genetics · doi:10.1038/ng1855 · Cited by 1,049 · see citing works

Boveri revisited: chromosomal instability, aneuploidy and tumorigenesis

Holland, A. J., & Cleveland, D. W. (2009) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2718 · Cited by 859 · see citing works

Hypoxia regulates TSC1/2–mTOR signaling and tumor suppression through REDD1-mediated 14–3–3 shuttling

DeYoung, M. P., Horak, P., Sofer, A., Sgroi, D., & Ellisen, L. W. (2008) · Genes & Development · doi:10.1101/gad.1617608 · Cited by 710 · see citing works

The Regulation of AMPK β1, TSC2, and PTEN Expression by p53: Stress, Cell and Tissue Specificity, and the Role of These Gene Products in Modulating the IGF-1-AKT-mTOR Pathways

Feng, Z., Hu, W., de Stanchina, E., Teresky, A. K., Jin, S., Lowe, S., & Levine, A. J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4149 · Cited by 633 · see citing works

The regulation of energy metabolism and the IGF-1/mTOR pathways by the p53 protein

Feng, Z., & Levine, A. J. (2010) · Trends in Cell Biology · doi:10.1016/j.tcb.2010.03.004 · Cited by 359 · see citing works

Coordination and communication between the p53 and IGF-1–AKT–TOR signal transduction pathways

Levine, A. J., Feng, Z., Mak, T. W., You, H., & Jin, S. (2006) · Genes & Development · doi:10.1101/gad.1363206 · Cited by 321 · see citing works

The New Era in Cancer Research

VARMUS, H. E. (2006) · Science · doi:10.1126/science.1126758 · Cited by 307 · see citing works

mTORC1 Signaling under Hypoxic Conditions Is Controlled by ATM-Dependent Phosphorylation of HIF-1α

Cam, H., Easton, J. B., High, A., & Houghton, P. J. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.10.030 · Cited by 266 · see citing works

ATM is down-regulated by N-Myc–regulated microRNA-421

Hu, H., Du, L., Nagabayashi, G., Seeger, R. C., & Gatti, R. A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907763107 · Cited by 261 · see citing works

Mutational Heterogeneity in Human Cancers: Origin and Consequences

Salk, J. J., Fox, E., & Loeb, L. A. (2009) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-121808-102113 · Cited by 249 · see citing works

Targeting DNA-PKcs and ATM with miR-101 Sensitizes Tumors to Radiation

Yan, D., Ng, W. L., Zhang, X., Wang, P., Zhang, Z., Mo, Y., Mao, H., Hao, C., Olson, J. J., Curran, W. J., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011397 · Cited by 227 · see citing works

Tel2 Regulates the Stability of PI3K-Related Protein Kinases

Takai, H., Wang, R. C., Takai, K., Yang, H., & de Lange, T. (2007) · Cell · doi:10.1016/j.cell.2007.10.052 · Cited by 215 · see citing works

Myc proteins as therapeutic targets

Gustafson, W. C., & Weiss, W. A. (2010) · Oncogene · doi:10.1038/onc.2009.512 · Cited by 199 · see citing works

Chronic Activation of mTOR Complex 1 Is Sufficient to Cause Hepatocellular Carcinoma in Mice

Menon, S., Yecies, J. L., Zhang, H., Howell, J. J., Nicholatos, J. W., Harputlugil, E., Bronson, R. T., Kwiatkowski, D. J., & Manning, B. D. (2012) · Science Signaling · doi:10.1126/scisignal.2002739 · Cited by 183 · see citing works

Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo

Johnsen, J. I., Segerström, L., Orrego, A., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210938 · Cited by 171 · see citing works

Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program

Houghton, P. J., Morton, C. L., Kolb, E. A., Gorlick, R. G., Lock, R. B., Carol, H., Reynolds, C. P., Maris, J. M., Keir, S. T., Billups, C. A., et al. (2007) · Pediatric Blood & Cancer · doi:10.1002/pbc.21296 · Cited by 159 · see citing works

Mechanisms of embryonal tumor initiation: Distinct roles for MycN expression and MYCN amplification

Hansford, L. M., Thomas, W. D., Keating, J., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401083101 · Cited by 159 · see citing works

miR-18a Impairs DNA Damage Response through Downregulation of Ataxia Telangiectasia Mutated (ATM) Kinase

Song, L., Lin, C., Wu, Z., Gong, H., Zeng, Y., Wu, J., Li, M., & Li, J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025454 · Cited by 149 · see citing works

Over-expression of miR-100 is responsible for the low-expression of ATM in the human glioma cell line: M059J

Ng, W. L., Yan, D., Zhang, X., Mo, Y., & Wang, Y. (2010) · DNA repair · doi:10.1016/j.dnarep.2010.08.007 · Cited by 123 · see citing works

Ataxia-Telangiectasia-Mutated ( ATM ) Gene in Head and Neck Squamous Cell Carcinoma

Ai, L., Vo, Q. N., Zuo, C., Li, L., Ling, W., Suen, J. Y., Hanna, E. Y., Brown, K. D., & Fan, C. (2004) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-082-3 · Cited by 104 · see citing works

N‐myc gene is amplified in alveolar rhabdomyosarcomas (RMS) but not in embryonal RMS

Dias, P., Kumar, P., Marsden, H. B., et al. (1990) · International Journal of Cancer · doi:10.1002/ijc.2910450403 · Cited by 71 · see citing works

microRNA Profiling Identifies Cancer-Specific and Prognostic Signatures in Pediatric Malignancies

Wei, J. S., Johansson, P. A., Chen, Q., Song, Y. K., Durinck, S., Wen, X., Cheuk, A., Smith, M. A., Houghton, P. J., Morton, C. L., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3287 · Cited by 54 · see citing works

The ATM/p53 pathway is commonly targeted for inactivation in squamous cell carcinoma of the head and neck (SCCHN) by multiple molecular mechanisms

Bolt, J., Vo, Q. N., Kim, W.-J., McWhorter, A. J., Thomson, J. L., Hagensee, M. E., Friedlander, P. L., Brown, K. D., & Gilbert, J. (2005) · Oral Oncology · doi:10.1016/j.oraloncology.2005.06.003 · Cited by 52 · see citing works

Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program

Houghton, P. J., Gorlick, R. G., Kolb, E. A., et al. (2011) · Pediatric Blood & Cancer · doi:10.1002/pbc.22935 · Cited by 39 · see citing works

miRNA Expression Profiling of the Murine TH-MYCN Neuroblastoma Model Reveals Similarities with Human Tumors and Identifies Novel Candidate MiRNAs

Terrile, M., Bryan, K. R., Vaughan, L. S., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028356 · Cited by 35 · see citing works

The Many Faces of Redundancy in DNA Replication ControlPreprint

Diffley, J. F. X. (2010) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2010.75.062 · Cited by 35 · see citing works

MYCN expression in human rhabdomyosarcoma cell lines and tumour samples

Toffolatti, L., Frascella, E., Ninfo, V., et al. (2002) · The Journal of Pathology · doi:10.1002/path.1068 · Cited by 32 · see citing works

Association of Ataxia Telangiectasia Mutated (ATM) Gene Mutation/Deletion with Rhabdomyosarcoma

Zhang, P., Bhakta, K. S., Puri, P., et al. (2003) · Cancer Biology & Therapy · doi:10.4161/cbt.231 · Cited by 21 · see citing works

Glutamine reliance in cell metabolism

Yoo, H. C., Yu, Y. C., Sung, Y., & Han, J. M. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-00504-8 · Cited by 1,021 · see citing works

Glutaminolysis and autophagy in cancer

Villar, V. H., Merhi, F., Djavaheri-Mergny, M., & Durán, R. V. (2015) · Autophagy · doi:10.1080/15548627.2015.1053680 · Cited by 143 · see citing works

Abstract 1726: Acquired resistance to rapamycin and mTOR kinase inhibitors is mediated by non-overlapping mutations in distinct sites in the mTOR protein

Rodrik-Outmezguine, V. S., Yao, Z., Mukherjee, R., Cai, L., Barratt, D. G., Ward, R., Klinowska, T. C. M., de Stanchina, E., Berger, M., Baselga, J. M., et al. (2014) · Cancer Research · doi:10.1158/1538-7445.am2014-1726 · Cited by 1 · see citing works

The functions of mTOR in ischemic diseases

Hwang, S., & Kim, H.-H. (2011) · BMB Reports · doi:10.5483/bmbrep.2011.44.8.506 · Cited by 58 · see citing works

Abstract 4621: Rapamycin inhibits the phosphorylation of mSin1 by targeting a new mTOR complex

Huang, S., Luo, Y., & Liu, L. (2016) · Cancer Research · doi:10.1158/1538-7445.am2016-4621

Small molecule H89 renders the phosphorylation of S6K1 and AKT resistant to mTOR inhibitors

Melick, C. H., & Jewell, J. L. (2020) · Biochemical Journal · doi:10.1042/bcj20190958 · Cited by 11 · see citing works

mTOR phosphorylated at S2448 binds to raptor and rictor

Rosner, M., Siegel, N., Valli, A., Fuchs, C., & Hengstschläger, M. (2009) · Amino Acids · doi:10.1007/s00726-008-0230-7 · Cited by 162 · see citing works